Johnson & Johnson (NYSE:JNJ) subsidiary LifeScan said today that it added support for the Apple (NSDQ:AAPL) HealthKit to its OneTouch Reveal mobile app for diabetes management. Diabetics using the OneTouch Reveal app can now view and blood sugar readings using their iPhone, Johnson & Johnson said. “For the nearly 400 million people worldwide living with diabetes, management needs to […]
LifeScan, has received regulatory clearance from the FDA for its OneTouch VerioSync blood glucose monitoring system, the first monitoring system to integrate with the Apple app store.
The app, called the OneTouch Reveal, is available on iPhone, iPad or iPod touch.
The system automatically sends blood glucose levels to mobile devices, displaying information in a 14-day summary with simple visual breakdowns. Patients can also share information via text or email or with their doctors or friends.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
London-based diabetes device maker Cellnovo inked a pact with J&J-owned LifeScan Inc. to incorporate that company’s technology into Cellnovo’s flagship mobile diabetes management system.
Cellnovo will integrate LifeScan’s blood glucose monitoring technology into the handset of its mobile system – an insulin patch pump and a touch screen that wirelessly transmits real-time data to a secure portal available to patients and doctors.